Dr. Chukwuemeka (Emeka) V. Ikpeazu
Claim this profileUniversity of Miami Miller School of Medicine-Sylvester Cancer Center
Expert in Cancer
Studies Recurrence
13 reported clinical trials
34 drugs studied
Area of expertise
1Cancer
Global LeaderStage IV
Stage III
KRAS positive
2Recurrence
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Chukwuemeka (Emeka) V. Ikpeazu is currently running
Fulvestrant + Binimetinib
for Breast Cancer
This trial is testing whether adding binimetinib to the usual treatment of fulvestrant can help patients with a specific type of advanced breast cancer. Fulvestrant works by blocking estrogen receptors on cancer cells, while binimetinib stops enzymes that help cancer grow. The goal is to see if this combination can better control the cancer compared to using fulvestrant alone.
Recruiting1 award Phase 219 criteria
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
More about Chukwuemeka (Emeka) V. Ikpeazu
Clinical Trial Related1 year of experience running clinical trials · Led 13 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Chukwuemeka (Emeka) V. Ikpeazu has experience with
- Paclitaxel
- Binimetinib
- Pembrolizumab
- Cisplatin
- Nilotinib Hydrochloride Monohydrate
- Fulvestrant
Breakdown of trials Chukwuemeka (Emeka) V. Ikpeazu has run
Cancer
Recurrence
Lung Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Chukwuemeka (Emeka) V. Ikpeazu specialize in?
Chukwuemeka (Emeka) V. Ikpeazu focuses on Cancer and Recurrence. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Chukwuemeka (Emeka) V. Ikpeazu currently recruiting for clinical trials?
Yes, Chukwuemeka (Emeka) V. Ikpeazu is currently recruiting for 10 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Chukwuemeka (Emeka) V. Ikpeazu has studied deeply?
Yes, Chukwuemeka (Emeka) V. Ikpeazu has studied treatments such as Paclitaxel, Binimetinib, Pembrolizumab.
What is the best way to schedule an appointment with Chukwuemeka (Emeka) V. Ikpeazu?
Apply for one of the trials that Chukwuemeka (Emeka) V. Ikpeazu is conducting.
What is the office address of Chukwuemeka (Emeka) V. Ikpeazu?
The office of Chukwuemeka (Emeka) V. Ikpeazu is located at: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida 33136 United States. This is the address for their practice at the University of Miami Miller School of Medicine-Sylvester Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.